[{"indications": "Indications\u00a0See under Dose", "name": "AMPHOTERICIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.2 Antifungal drugs", "5.2.3 Polyene antifungals", "AMPHOTERICIN"], "cautions": "Cautions\u00a0when given parenterally, toxicity common\r\n(close supervision necessary and test dose required;\r\nsee Anaphylaxis below); hepatic and renal function tests,\r\nblood counts, and plasma electrolyte (including plasma-potassium and\r\nmagnesium concentration) monitoring required; corticosteroids (avoid except to control reactions); avoid rapid infusion (risk of arrhythmias); interactions: Appendix 1 (amphotericin)Anaphylaxis\u00a0Anaphylaxis occurs rarely\r\nwith any intravenous amphotericin product and a\r\ntest dose is advisable before the first infusion; the\r\npatient should be carefully observed for at least 30 minutes after\r\nthe test dose. Prophylactic antipyretics or hydrocortisone should only be used in patients who have\r\npreviously experienced acute adverse reactions (in whom continued\r\ntreatment with amphotericin is essential)", "side-effects": "Side-effects\u00a0when given parenterally, anorexia, nausea and\r\nvomiting, diarrhoea, epigastric pain; febrile reactions, headache,\r\nmuscle and joint pain; anaemia; disturbances in renal function (including\r\nhypokalaemia and hypomagnesaemia) and renal toxicity; also cardiovascular\r\ntoxicity (including arrhythmias, blood pressure changes), blood disorders,\r\nneurological disorders (including hearing loss, diplopia, convulsions,\r\nperipheral neuropathy, encephalopathy), abnormal liver function (discontinue\r\ntreatment), rash, anaphylactoid reactions (see Anaphylaxis, above);\r\npain and thrombophlebitis at injection site", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3971.htm", "doses": ["By intravenous infusion, see preparations", "Different preparations of intravenous amphotericin\r\nvary in their pharmacodynamics, pharmacokinetics, dosage, and administration;\r\nthese preparations should not be considered interchangeable.\r\nTo avoid confusion, prescribers should specify the brand to be dispensed.", "by intravenous infusion, systemic fungal\r\ninfections, initial test dose of 1\u00a0mg over 20\u201330 minutes then 250\u00a0micrograms/kg\r\ndaily, gradually increased over 2\u20134 days, if tolerated, to 1\u00a0mg/kg\r\ndaily; max. (severe infection) 1.5\u00a0mg/kg daily or on alternate days; child under 18 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0not known to be harmful but manufacturers advise\r\navoid unless potential benefit outweighs risk"}, {"indications": "Indications\u00a0See under Dose", "name": "AMPHOTERICIN Lipid formulations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.2 Antifungal drugs", "5.2.3 Polyene antifungals", "AMPHOTERICIN", "Lipid formulations"], "cautions": "Cautions\u00a0when given parenterally, toxicity common\r\n(close supervision necessary and test dose required;\r\nsee Anaphylaxis below); hepatic and renal function tests,\r\nblood counts, and plasma electrolyte (including plasma-potassium and\r\nmagnesium concentration) monitoring required; corticosteroids (avoid except to control reactions); avoid rapid infusion (risk of arrhythmias); interactions: Appendix 1 (amphotericin)Anaphylaxis\u00a0Anaphylaxis occurs rarely\r\nwith any intravenous amphotericin product and a\r\ntest dose is advisable before the first infusion; the\r\npatient should be carefully observed for at least 30 minutes after\r\nthe test dose. Prophylactic antipyretics or hydrocortisone should only be used in patients who have\r\npreviously experienced acute adverse reactions (in whom continued\r\ntreatment with amphotericin is essential)", "side-effects": "Side-effects\u00a0when given parenterally, anorexia, nausea and\r\nvomiting, diarrhoea, epigastric pain; febrile reactions, headache,\r\nmuscle and joint pain; anaemia; disturbances in renal function (including\r\nhypokalaemia and hypomagnesaemia) and renal toxicity; also cardiovascular\r\ntoxicity (including arrhythmias, blood pressure changes), blood disorders,\r\nneurological disorders (including hearing loss, diplopia, convulsions,\r\nperipheral neuropathy, encephalopathy), abnormal liver function (discontinue\r\ntreatment), rash, anaphylactoid reactions (see Anaphylaxis, above);\r\npain and thrombophlebitis at injection site", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3973.htm", "doses": ["By intravenous infusion, see preparations", "Different preparations of intravenous amphotericin\r\nvary in their pharmacodynamics, pharmacokinetics, dosage, and administration;\r\nthese preparations should not be considered interchangeable.\r\nTo avoid confusion, prescribers should specify the brand to be dispensed.", "Name[AmBisome\u00ae (Gilead) ] Intravenous infusion, powder for\r\nreconstitution, amphotericin 50\u00a0mg encapsulated\r\nin liposomes, net price 50-mg vial = \u00a396.69Electrolytes: Na+\u00a0<\u00a00.5\u00a0mmol/vialExcipients  include sucrose 900\u00a0mg/vialDose\u00a0by intravenous infusion, severe systemic\r\nor deep mycoses where toxicity (particularly nephrotoxicity) precludes\r\nuse of conventional amphotericin; suspected or\r\nproven infection in febrile neutropenic patients unresponsive to broad-spectrum\r\nantibacterials; aspergillosis, initial test dose 1\u00a0mg\r\nover 10 minutes then 3\u00a0mg/kg once daily; max. 5\u00a0mg/kg once daily [unlicensed\r\ndose]; child under 18 years see BNF for ChildrenVisceral leishmaniasis, see section 5.4.5 and product literature"], "pregnancy": "Pregnancy\u00a0not known to be harmful but manufacturers advise\r\navoid unless potential benefit outweighs risk"}]